Work

Molecular Features Associated with Response to Combination Therapy with Enasidenib (ENA) Plus Azacitidine (AZA) in Newly Diagnosed IDH2-Mutated Acute Myeloid Leukemia (AML)

Year: 2022

Type: article

Source: Blood

DOI: 10.1182/blood-2022-158967

Authors: Alberto Risueño, Wendy L. See, Courtney D. DiNardo, Hartmut Döhner, Eytan Stein, Amir T. Fathi, Paresh Vyas, Lynn Quek, Thomas Prebet, Anita K. Gandhi, Maroof Hasan

Institutions: Bristol-Myers Squibb (United States), The University of Texas MD Anderson Cancer Center, University Hospital Ulm, Memorial Sloan Kettering Cancer Center, Massachusetts General Hospital, University of Oxford, King's College Hospital NHS Foundation Trust, King's College Hospital

Language: English

Topic: Acute Myeloid Leukemia Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4310106213

FWCI:

Cites:

Cited by:

Related to: 10